<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Jacobio Pharmaceuticals Group Co Lt — News on 6ix</title>
<link>https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt</link>
<description>Latest news and press releases for Jacobio Pharmaceuticals Group Co Lt on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sun, 21 Dec 2025 12:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/jacobio-pharmaceuticals-group-co-lt" rel="self" type="application/rss+xml" />
<item>
<title>Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73</title>
<link>https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-pharma-enters-global-exclusive-license-agreement-with-astrazeneca-for-pan-kras-inhibitor-jab-23e73</link>
<guid isPermaLink="true">https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-pharma-enters-global-exclusive-license-agreement-with-astrazeneca-for-pan-kras-inhibitor-jab-23e73</guid>
<pubDate>Sun, 21 Dec 2025 12:15:00 GMT</pubDate>
<description>Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73. AstraZeneca will receive exclusive development and commercialisation rights outside of China, while Jacobio and AstraZeneca will jointly develop and commercialise JAB-23E73 in China.</description>
</item>
<item>
<title>Jacobio Presents Pre-Clinical Data of Pan-KRAS Inhibitor (JAB-23E73) at AACR-NCI-EORTC International Conference</title>
<link>https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-presents-pre-clinical-data-of-pan-kras-inhibitor-jab-23e73-at-aacr-nci-eortc-international-conference</link>
<guid isPermaLink="true">https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-presents-pre-clinical-data-of-pan-kras-inhibitor-jab-23e73-at-aacr-nci-eortc-international-conference</guid>
<pubDate>Fri, 24 Oct 2025 00:00:00 GMT</pubDate>
<description>Jacobio Pharma (1167.HK) announced that it presented the pre-clinical data of its internally discovered pan-KRAS inhibitor JAB-23E73 in a poster presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.</description>
</item>
<item>
<title>Jacobio Pharma Announces Strategic Partnership with Oceanpine Capital to Focus on Core Oncology Pipeline</title>
<link>https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-pharma-announces-strategic-partnership-with-oceanpine-capital-to-focus-on-core-oncology-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-pharma-announces-strategic-partnership-with-oceanpine-capital-to-focus-on-core-oncology-pipeline</guid>
<pubDate>Wed, 15 Oct 2025 15:05:00 GMT</pubDate>
<description>Jacobio Pharma (1167.HK) today announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity Transfer Agreement with Oceanpine Capital and an industry partner. Under the agreement, Oceanpine Capital will acquire 80% equity interest in Beijing Jacoray Pharmaceutical Technology Co., Ltd. ("Jacoray") for a total consideration of RMB 200 million (comprising RMB 125 million as the upfront payment and an additional RMB 75 m</description>
</item>
<item>
<title>Jacobio Chairman and Concerted Parties Increase Shareholding by Nearly HK$100 Million, Demonstrating Confidence in Long-term Growth</title>
<link>https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-chairman-and-concerted-parties-increase-shareholding-by-nearly-hkdollar100-million-demonstrating-confidence-in-long-term-growth</link>
<guid isPermaLink="true">https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-chairman-and-concerted-parties-increase-shareholding-by-nearly-hkdollar100-million-demonstrating-confidence-in-long-term-growth</guid>
<pubDate>Fri, 26 Sep 2025 00:47:00 GMT</pubDate>
<description>Jacobio Pharmaceuticals (1167.HK) today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the Company by 11.06 million shares, representing a total investment of approximately HK$96.34 million. This action underscores their strong confidence in the Company's long-term growth prospects.</description>
</item>
<item>
<title>Jacobio Pharma Announces 2025 Interim Results</title>
<link>https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-pharma-announces-2025-interim-results</link>
<guid isPermaLink="true">https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-pharma-announces-2025-interim-results</guid>
<pubDate>Fri, 29 Aug 2025 16:25:00 GMT</pubDate>
<description>Jacobio Pharma (1167.HK) today announced its interim results for the six months ended June 30, 2025.</description>
</item>
<item>
<title>Jacobio's IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted</title>
<link>https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobios-ind-for-phase-iii-clinical-trial-of-bet-inhibitor-jab-8263-in-autoimmune-diseases-has-been-accepted</link>
<guid isPermaLink="true">https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobios-ind-for-phase-iii-clinical-trial-of-bet-inhibitor-jab-8263-in-autoimmune-diseases-has-been-accepted</guid>
<pubDate>Thu, 03 Jul 2025 00:30:00 GMT</pubDate>
<description>Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibitor JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in China and has been accepted. According to new regulatory guidelines, the review of JAB-8263's IND application is expected to be completed within 30 working days</description>
</item>
<item>
<title>Jacobio Pharma Announces 2024 Annual Results</title>
<link>https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-pharma-announces-2024-annual-results</link>
<guid isPermaLink="true">https://6ix.com/company/jacobio-pharmaceuticals-group-co-lt/news/jacobio-pharma-announces-2024-annual-results</guid>
<pubDate>Wed, 19 Mar 2025 13:42:00 GMT</pubDate>
<description>Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense of RMB330 million. Major operating and financing activities generated RMB320 million cash inflows. By the end of 2024, cash and bank balances and bank credit balances amounted to RMB1.45 billion. Jacobio also announced recent business progress and expected milestones.</description>
</item>
</channel>
</rss>